Eli Lilly (LLY)
1,149.15
+0.00 (0.00%)
NYSE· Last Trade: Jun 9th, 4:42 AM EDT
Detailed Quote
| Previous Close | 1,149.15 |
|---|---|
| Open | - |
| Bid | 1,156.04 |
| Ask | 1,160.00 |
| Day's Range | N/A - N/A |
| 52 Week Range | 623.78 - 1,182.73 |
| Volume | 5,945 |
| Market Cap | 1.10T |
| PE Ratio (TTM) | 50.07 |
| EPS (TTM) | 22.9 |
| Dividend & Yield | 6.920 (0.60%) |
| 1 Month Average Volume | 3,239,943 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
The pharma giant is well-positioned to lead the $200 billion global obesity treatment market.
Via The Motley Fool · June 8, 2026

These stocks may deliver gains during any market environment.
Via The Motley Fool · June 8, 2026
Infectious disease could fuel Eli Lilly's next growth phase.
Via The Motley Fool · June 8, 2026
Marvell’s leap into the S&P 500 caps a sharp AI-chip rebound that helped steady U.S. stocks, today, June 8, 2026.
Via The Motley Fool · June 8, 2026
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.1% in the afternoon session after the company reported positive Phase 3 ...
Via StockStory · June 8, 2026
Zealand Pharma's stock is cratering today after disappointing results from a late-stage trial of its GLP-1 dual-receptor agonist drug.
Via The Motley Fool · June 8, 2026
Eli Lilly emerged as the "clear winner" from the ADA meeting last weekend in New Orleans, an analyst said following the event.
Via Investor's Business Daily · June 8, 2026
How does an average annual gain of 18% over the past decade sound?
Via The Motley Fool · June 8, 2026
Eli Lilly reports Foundayo delivered significant weight loss across menopausal stages, with up to 14.4% reductions at 72 weeks.
Via Benzinga · June 8, 2026

Getting exposure to high-profile IPOs is easier than ever through low-cost index funds and ETFs.
Via The Motley Fool · June 8, 2026

Investor Jordi Visser says Eli Lilly could become the world's largest company and AI leader within five years due to its AI advantage.
Via Benzinga · June 8, 2026
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a...
Via StockStory · June 7, 2026
The Vanguard Dividend Appreciation ETF is the perfect fit for investors looking to build a portfolio around high-quality companies that pay growing dividends.
Via The Motley Fool · June 7, 2026
Novo Nordisk could maintain this latest early-mover advantage longer than you think.
Via The Motley Fool · June 7, 2026
Micron has had a turnaround for the ages, going from a free cash flow negative company to a $1 trillion valuation in a little over a year.
Via The Motley Fool · June 6, 2026
Eli Lilly just announced a trio of acquisitions that will allow it to build a new business focused on infectious diseases.
Via The Motley Fool · June 6, 2026
Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable.
Via The Motley Fool · June 6, 2026
International growth could help push Lilly even higher.
Via The Motley Fool · June 6, 2026
Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake.
Via The Motley Fool · June 6, 2026
The stock market appears to be rotating into health care.
Via Investor's Business Daily · June 6, 2026
Via Benzinga · June 5, 2026
One fund backs medical breakthroughs and charity, while the other favors industry giants and steady income. Compare their strategies and portfolio makeup.
Via The Motley Fool · June 5, 2026
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
Via The Motley Fool · June 5, 2026
It's another step in Eli Lilly's quest to cement its lead in the chronic weight management market.
Via The Motley Fool · June 5, 2026
What Happened? Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 6.3% in the afternoon session after the company announced its Weight Wat...
Via StockStory · June 4, 2026
